IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis
Panelists discuss how IL-13 targeting biologics, including dupilumab, tralokinumab, and lebrikizumab, are advancing the treatment of atopic dermatitis, improving efficacy, safety, and patient outcomes, while addressing key challenges in diagnosis and treatment selection.
EP. 1: Heterogenous Presentation Of Atopic Dermatitis
December 24th 2024Panelists discuss how the clinical heterogeneity of Atopic Dermatitis (AD) presents diagnostic challenges, with varying criteria for pediatric and adult-onset AD, highlighting the need for age-specific approaches to accurately diagnose and treat the condition.
EP. 2: Use of Biopsy and Diagnosing New-Onset AD
January 2nd 2025Panelists discuss how to confirm the diagnosis of atopic dermatitis (AD) when in doubt, emphasizing the importance of clinical evaluation, family history, and skin testing, and share strategies for approaching adult patients with new-onset AD, including thorough patient history and targeted management.
